At a glance
A ghrelin-mimetic peptide studied in endocrine and appetite research.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Appetite changes and endocrine responses are relevant to the cited research. Claims about muscle growth or recovery require their own outcome evidence.[5][5][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of GHRP-6.
A comprehensive adverse-effect profile is not established by the source record. Consult the cited studies for what was measured and what remains uncertain.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 2 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~0.67 mg/mL)
| Week/Phase | Dose per Injection (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 15 units (0.15 mL) |
| Weeks 3–4 | 200 mcg | 30 units (0.30 mL) |
| Weeks 5–12 | 300 mcg | 45 units (0.45 mL) |
Frequency: Inject three times daily subcutaneously, spaced at least 4 hours apart (morning, midday, bedtime). GHRP-6 has a short half-life of approximately 2.5 hours[4], making multiple daily injections more effective than once-daily dosing for sustained GH elevation[1]. Each injection should be administered on an empty stomach (2–3 hours after meals, 30 minutes before eating) to maximize GH release[2].
Additional schedule context & duration
Concise summary of the three-times-daily regimen.
- Goal: Stimulate pulsatile GH release to support muscle growth, fat loss, and recovery[2][5].
- Schedule: Three subcutaneous injections daily for 8–12 weeks, spaced at least 4 hours apart.
- Dose Range: 100–300 mcg per injection with gradual titration (300–900 mcg total daily).
- Reconstitution: 3.0 mL per 2 mg vial (~0.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; use within 7 days.
Suggested titration approach with multiple daily doses.
- Start: 100 mcg per injection, 3× daily (300 mcg total) for Weeks 1–2.
- Increase: 200 mcg per injection, 3× daily (600 mcg total) for Weeks 3–4.
- Target: 300 mcg per injection, 3× daily (900 mcg total) for Weeks 5–12.
- Timing: On empty stomach; space injections at least 4 hours apart; wait 30 minutes before eating.
- Cycle Length: 8–12 weeks; rotate injection sites to prevent tissue irritation.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to avoid foaming; do not shake.
- Gently swirl or roll the vial until the powder is completely dissolved.
- Label with date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 7 days of reconstitution for optimal potency.
Storage Instructions
Proper storage preserves peptide quality and potency.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions with desiccant if available.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days[6].
- Avoid freeze-thaw cycles: Do not refreeze reconstituted solution; prepare aliquots if extended storage is needed.
- Allow vials to reach room temperature before opening to minimize condensation.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[10][11].
- Preparation: Clean the vial stopper and injection site with alcohol swabs; allow to dry completely.
- Drawing the dose: Use a new sterile insulin syringe; draw the calculated units and check for air bubbles.
- Site selection: Rotate between abdomen (2+ inches from navel), outer thighs, and upper arms. Avoid repeatedly injecting the same spot[8][12].
- Technique: Pinch a skinfold; insert needle at 45–90° angle into subcutaneous tissue (angle depends on needle length and body fat)[10][11].
- Administration: Do not aspirate for subcutaneous injections. Inject slowly and steadily; hold for a few seconds before withdrawing[10].
- Disposal: Immediately dispose of used syringes and needles in a puncture-proof sharps container. Never reuse needles[7].
Materials & quantity planning
Source materials checklist · 2 mg
Plan based on a 12-week protocol with three-times-daily injections and gradual titration.
-
Peptide Vials (GHRP-6, 2 mg each):
- 12 weeks ≈ 32 vials (based on gradual titration to 300 mcg × 3 daily)
-
Insulin Syringes (U-100):
- Per week: 21 syringes (3/day × 7 days)
- 12 weeks: 252 syringes (recommend 3 × 100-count boxes)
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 12 weeks (32 vials): 96 mL → 10 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site per injection.
- Per week: 42 swabs (2 per injection × 3 daily × 7 days)
- 12 weeks: 504 swabs → recommend 6 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 2 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
European Journal of Endocrinology (1997) — Growth hormone-releasing peptides: comprehensive review of GHRP mechanisms and effects (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Public health resource
Clinical Medicine Insights: Cardiology (2017) — Synthetic GHRPs: historical appraisal of cytoprotective effects and mechanisms (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Source document
Wikipedia — GHRP-6: structure, pharmacology, and mechanism of action overview (opens in a new tab)en.wikipedia.org
Back to overview ↑ - 04
Research publication
European Journal of Pharmaceutical Sciences (2013) — Pharmacokinetic study of GHRP-6 in healthy male volunteers (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
Sexual Medicine Reviews (2018) — Safety and efficacy of growth hormone secretagogues (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Public health resource
CDC (2024) — Preventing unsafe injection practices: basic injection safety guidelines (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
CDC (2024) — 4 ways to take insulin: injection sites and rotation strategies (opens in a new tab)www.cdc.gov
Back to overview ↑ - 10
Public health resource
CDC (2024) — Vaccine administration: subcutaneous injection technique (fact sheet) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 11
Public health resource
CDC (2024) — Vaccine administration: during vaccination best practices (opens in a new tab)www.cdc.gov
Back to overview ↑ - 12
Public health resource
Clinical Diabetes (2019) — The injection technique factor: what you don’t know or teach can make a difference (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.